Dianthus Therapeutics Inc. (DNTH)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Dianthus Therapeutics Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Dianthus Therapeutics Inc. (DNTH) has returned 103.64% so far this year and 362.62% over the past 12 months.

Based on dividend-adjusted daily data since Sep 12, 2023, DNTH's average daily return is +0.44%, while the average monthly return is +9.21%. At this rate, your investment would double in approximately 0.7 years.

Historically, 58% of months were positive and 42% were negative. The best month was Jan 2024 with a return of +82.7%, while the worst month was Apr 2024 at -28.8%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 3 months.

On a daily basis, DNTH closed higher 51% of trading days. The best single day was Jan 22, 2024 with a return of +37.2%, while the worst single day was Jan 10, 2024 at -19.3%.

Dianthus Therapeutics Inc. has an annualized alpha of 150.52%, beta of 1.13, and R² of 0.05 versus S&P 500 Index. Calculated based on daily prices since September 13, 2023.

• This stock captured 470.71% of S&P 500 Index gains and tended to rise during its downturns (downside capture of -17.71%) — a profile typical of hedging or uncorrelated assets.
• R² of 0.05 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

DNTH ranks 99 for risk / return — in the top 99% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for Dianthus Therapeutics Inc. (DNTH) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Dianthus Therapeutics Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Dianthus Therapeutics Inc. was 53.48%, occurring on Apr 8, 2025. Recovery took 105 trading sessions.

The current Dianthus Therapeutics Inc. drawdown is 3.45%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Dianthus Therapeutics Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Dianthus Therapeutics Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.